Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Pharmacogenomics J ; 18(2): 238-244, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-28374859

RESUMEN

Arginase 1 (ARG1) and arginase 2 (ARG2) compete with nitric oxide synthases for the substrate l-arginine. Here we aim to assess whether arginase 1 and 2 plasma levels, plasma arginase activity or genetic factors are associated with altered responsiveness to sildenafil. We studied 71 post-prostatectomy erectile dysfunction (ED) patients (PED group) and 72 clinical ED patients (CED). Patients responded to the International Index of Erectile Function questionnaire before and after the treatment. We found positive and negative correlations between plasma levels of arginase 1 and sildenafil responsiveness in the PED and CED groups, respectively. PED group also presented negative correlation between plasma arginase activity and sildenafil responsiveness. Sildenafil poor responders have shown higher plasma arginase activity in PED and higher arginase 1 levels on CED groups. In addition, variant genotypes for the rs2781659, rs2781667 and rs17599586 polymorphisms were associated with reduced arginase activity, as well as the GTTT ARG1 haplotype in CED group.


Asunto(s)
Arginasa/sangre , Arginasa/genética , Disfunción Eréctil/sangre , Disfunción Eréctil/genética , Citrato de Sildenafil/sangre , Vasodilatadores/sangre , Adulto , Anciano , Arginasa/antagonistas & inhibidores , Activación Enzimática/efectos de los fármacos , Activación Enzimática/fisiología , Disfunción Eréctil/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo Genético/genética , Citrato de Sildenafil/farmacología , Citrato de Sildenafil/uso terapéutico , Resultado del Tratamiento , Vasodilatadores/farmacología , Vasodilatadores/uso terapéutico
2.
Pharmacogenomics J ; 13(5): 437-42, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23007311

RESUMEN

Vascular endothelial growth factor (VEGF) is a cytokine involved in angiogenesis and is closely related to the nitric oxide-cyclic guanosine monophosphate pathway, a target for sildenafil. We investigated for the first time whether three clinically relevant polymorphisms in the VEGF gene are associated with altered responsiveness to sildenafil treatment in postoperative erectile dysfunction (PED) and clinical erectile dysfunction (CED). We determined VEGF genotypes for three polymorphisms in VEGF promoter: -2578C>A (rs699947), -1154G>A (rs1570360) and -634G>C (rs2010963) in 126 patients with erectile dysfunction (ED; 66 patients with PED and 60 patients with CED). The patients were classified as good or poor responders to sildenafil (GR and PR groups, respectively) according to their responses with basis on the changes in five-item version of the International Index for Erectile Function (5-IIEF). We found an association of the -1154AA genotype with PR in both PED and CED patients (P<0.05), whereas the -2578AA and the -2578CA genotypes were associated with PR only in the CED group (P<0.05). The AAG haplotype was more common in PR than in GR patients (38% versus 20%, respectively; P=0.032) in the CED group, thus increasing the risk for a worse response to sildenafil (odds ratio, OR=2.33, 95% confidence interval, CI=1.07-5.09). However, this finding does not resist to Bonferroni's correction (P>0.0125). Our results indicate that VEGF polymorphisms affect the responsiveness of PED and CED patients to sildenafil. These findings may help to improve the therapy of patients with ED.


Asunto(s)
Disfunción Eréctil/tratamiento farmacológico , Disfunción Eréctil/genética , Piperazinas/uso terapéutico , Sulfonas/uso terapéutico , Agentes Urológicos/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/genética , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo Genético , Regiones Promotoras Genéticas , Purinas/uso terapéutico , Citrato de Sildenafil
3.
Pharmacogenomics J ; 13(2): 189-96, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22064666

RESUMEN

Erectile dysfunction (ED) is usually treated with sildenafil. Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil. We studied 118 patients; 63 patients had ED secondary to radical prostatectomy (PED) and 55 had organic, clinical ED. eNOS genotypes for three eNOS polymorphisms (T(-786)C, rs2070744; a variable number of tandem repeats (VNTR) in intron 4; and Glu298Asp, rs1799983) were determined, and eNOS haplotypes were estimated using PHASE 2.1. The clinical responses to sildenafil were evaluated and the patients were classified as good responders (GR) or poor responders (PR) when their changes in five-item version of International Index for Erectile Function questionnaire were above or below the median value. The TC/CC genotypes and the C allele for the T(-786)C polymorphism were more common in GR, compared with PR patients with PED. However, the 4b4a/4a4a genotypes and the 4a allele for the VNTR polymorphism in intron 4 were more common in GR, compared with PR patients with clinical ED. The C-4a-Glu haplotype was more common in GR than in PR patients with PED. Conversely, the T-4b-Asp haplotype was less common in GR than in PR patients with PED. No other significant differences were found. Our findings show evidence that eNOS polymorphisms affect the responses of PED and clinical ED patients to sildenafil.


Asunto(s)
Disfunción Eréctil/tratamiento farmacológico , Disfunción Eréctil/genética , Óxido Nítrico Sintasa de Tipo III/genética , Piperazinas/administración & dosificación , Sulfonas/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores Farmacológicos , Disfunción Eréctil/patología , Genotipo , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Repeticiones de Minisatélite , Piperazinas/efectos adversos , Polimorfismo de Nucleótido Simple , Prostatectomía , Purinas/administración & dosificación , Purinas/efectos adversos , Citrato de Sildenafil , Sulfonas/efectos adversos , Encuestas y Cuestionarios
4.
Int J Impot Res ; 24(1): 38-43, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-21918531

RESUMEN

Erectile dysfunction (ED) may reflect vascular alterations associated with imbalanced matrix metalloproteinases (MMPs) activities. However, no previous study has compared MMPs levels in ED patients with those found in healthy subjects. We measured the circulating MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in ED patients, with or without diabetes mellitus (DM), and in healthy controls. We studied 28 healthy men (control group), 35 men with ED (ED group), and 33 men with ED and DM (ED/DM group). MMP-2, MMP-9, TIMP-1 and TIMP-2 plasma levels were measured by enzyme-linked immunosorbent assay and zymography. We found no differences in MMP-9 levels (P>0.05) among groups. However, while patients in the ED group had similar TIMP-1 levels compared with those found in the control group, we found higher TIMP-1 levels and lower MMP-9/TIMP-1 ratios in the ED/DM group compared with controls (P<0.05). While both groups of patients (ED and ED/DM) had slightly lower MMP-2 levels compared with controls (P<0.05), we found no differences in TIMP-2 levels among the study groups (P>0.05), and no differences in MMP-2/TIMP-2 ratios (P>0.05). We found evidence indicating lack of significant alterations in circulating net MMP-9 and MMP-2 activities in patients with ED, and lower net MMP-9 activity in diabetic patients with ED.


Asunto(s)
Inhibidores Enzimáticos/sangre , Disfunción Eréctil/enzimología , Inhibidores de la Metaloproteinasa de la Matriz , Metaloproteinasas de la Matriz/sangre , Adulto , Anciano , Complicaciones de la Diabetes , Diabetes Mellitus/enzimología , Disfunción Eréctil/complicaciones , Humanos , Masculino , Metaloproteinasa 2 de la Matriz/sangre , Metaloproteinasa 9 de la Matriz/sangre , Persona de Mediana Edad , Inhibidor Tisular de Metaloproteinasa-1/sangre , Inhibidor Tisular de Metaloproteinasa-2/sangre
5.
J Bioenerg Biomembr ; 27(2): 249-58, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7592572

RESUMEN

This article presents direct measurements of large-conductance cation channel (G = 730 pS in 100/50 mM KCl; PK+/PCl- = 2.8) and light-induced current (photocurrent) in chloroplasts from C4 plants, Amaranthus hybridus and Zea mays, using the conventional patch-clamp technique. It was shown that preillumination of chloroplast gave rise to a fast decaying transient (tau approximately equal to 6 ms) in the light-induced current for the second and following light pulses. This transient increase of photocurrent was interpreted as a consequence of photoreducing of the redox pool between photosystems.


Asunto(s)
Cloroplastos/metabolismo , Canales Iónicos/metabolismo , Cloroplastos/efectos de la radiación , Oscuridad , Transporte de Electrón , Canales Iónicos/efectos de la radiación , Cinética , Luz , Oxidación-Reducción , Fotobiología , Fotosíntesis , Zea mays
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA